股票 
板块 
用户 
资讯 Swipe Left for English News→
2026年5月19-21日，CDMO Live Europe 2026 将在荷兰鹿特丹世界贸易中心（WTC Beursplein）隆重举行。本届展会将汇聚超过650名参会者、100家CDMO合作伙伴，并通过独具特色的PartnerMatch系统促成2,000余场一对一精准对接会议，为全球制药企业和CDMO服务商搭建高效、深度的合作桥梁。
今年，博腾将首次亮相本次展会#S45展位，全面展示公司在小分子药物、多肽与寡核苷酸药物、蛋白与偶联药物以及细胞与基因治疗药物领域全球化、端到端的CDMO服务能力。
聚焦CDMO：全生命周期服务能力全面呈现
在本次CDMO Live Europe 2026上，博腾将重点展示以下核心能力：
全球领先的技术平台
依托领先的研发和生产能力，博腾已建成覆盖小分子原料药、小分子制剂、新分子（多肽/寡核苷酸/蛋白与偶联药物）、细胞与基因治疗四大业务板块的技术平台。公司在连续反应，药物结晶，生物催化，光/电化学等领域拥有行业领先的技术积累。
端到端CDMO解决方案
博腾提供从工艺开发（Process Development）、中试生产（Pilot-Scale Production）到商业化GMP制造的一体化服务。无论您的项目处于临床前研究阶段，还是即将步入商业化生产，博腾均能提供定制化、高质量的解决方案。
欢迎全球合作伙伴莅临博腾展位#S45，或通过以下方式预约与博腾商务团队的专属会谈，共同挖掘合作新机遇：
点击“”访问博腾官方网站：线下会议专区
发送邮件至：business@portonpharma.com
博腾股份成立于2005年，主要为全球药企、生物科技公司、科研机构等提供从临床前研究到药品上市全生命周期所需的小分子药物、多肽与寡核苷酸药物、蛋白与偶联药物以及细胞与基因治疗药物等一站式服务解决方案，研发、生产、运营场地覆盖中国（重庆、上海、四川、江苏、江西、湖北）、美国、比利时、瑞士和丹麦等地。我们始终坚持以客户为中心，致力于为客户提供创新、可靠的全球化、端到端CDMO服务，让好药更早惠及大众。
Porton Pharma Solutions, a global company with over 4,300 employees and R&D and GMP-compliant manufacturing facilities, today announced its first participation in CDMO Live Europe 2026.
Taking place May 19-21, 2026 at the Rotterdam World Trade Center (Beursplein 37/Meent 110, 3011 AA Rotterdam, Netherlands), CDMO Live Europe 2026 will bring together 650+ attendees and 100 CDMO partners, facilitating 2,000+ PartnerMatch meetings over three days of curated networking and strategic collaboration.
Porton will welcome partners at Booth #S45, showcasing its comprehensive, global end-to-end CDMO capabilities across Small Molecules, TIDEs, Biologics and Conjugates (ADCs, AOCs, DACs, PDCs, RDCs, etc.), as well as Advanced Therapy Medicinal Products.
What Porton Will Present at Booth #S45
Global State-of-the-Art Technology Platforms
With cutting-edge R&D and manufacturing capabilities, Porton has established technology platforms spanning small molecule APIs, small molecule drug products, new modalities, and Advanced Therapy Medicinal Products. The company holds expertise in Flow Chemistry, Crystallization, Biocatalysis, as well as Photochemistry and Electrochemistry etc.
End-to-End CDMO Solutions
Porton provides integrated services from process development and pilot-scale production to commercial GMP manufacturing. Whether your program is in preclinical research or ready for commercial launch, Porton delivers tailored, high-quality solutions.
To maximize efficiency and value, global partners are cordially invited to schedule exclusive meetings with Porton's business development teams:
Visit our official website's Events page.
Email us at business@portonpharma.com.
Founded in 2005, Porton Pharma Solutions Ltd. is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products from pre-clinical to commercialization stages.
评论 (0)